Woodline Partners LP Phathom Pharmaceuticals, Inc. Transaction History

Woodline Partners LP

$11 Billion
Q3 2024

A detailed history of Woodline Partners LP transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 2,573,412 shares of PHAT stock, worth $19.3 Million. This represents 0.42% of its overall portfolio holdings.

Number of Shares

2,573,412

Previous 785,990 227.41%

Holding current value

$19.3 Million

Previous $8.1 Million 474.76%

% of portfolio

0.42%

Previous 0.08%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$10.25 - $19.5 $18.3 Million - $34.9 Million	1,787,422 Added 227.41%	2,573,412 $46.5 Million
Q2 2024 Aug 14, 2024	BUY	$8.97 - $12.05 $1.97 Million - $2.65 Million	219,551 Added 38.76%	785,990 $8.1 Million
Q1 2024 May 15, 2024	SELL	$6.21 - $11.05 $3.29 Million - $5.85 Million	-529,682 Reduced 48.32%	566,439 $6.02 Million
Q4 2023 Feb 14, 2024	BUY	$6.99 - $10.71 $2.49 Million - $3.81 Million	356,100 Added 48.12%	1,096,121 $10 Million
Q3 2023 Nov 14, 2023	BUY	$10.26 - $15.7 $680,576 - $1.04 Million	66,333 Added 9.85%	740,021 $7.67 Million
Q2 2023 Aug 14, 2023	BUY	$7.28 - $14.32 $4.9 Million - $9.65 Million	673,688 New	673,688 $9.65 Million
Q4 2021 Feb 14, 2022	SELL	$17.83 - $33.15 $533,170 - $991,284	-29,903 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$30.69 - $36.83 $917,723 - $1.1 Million	29,903 New	29,903 $960,000
Q2 2021 Aug 16, 2021	SELL	$32.66 - $39.87 $1.36 Million - $1.66 Million	-41,678 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$33.86 - $48.68 $1.41 Million - $2.03 Million	41,678 New	41,678 $1.57 Million

Others Institutions Holding PHAT

# of Institutions

144

Shares Held

73.6M

Call Options Held

42.3K

Put Options Held

45.7K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $294M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Account

Woodline Partners LP Phathom Pharmaceuticals, Inc. Transaction History